Gene Panel Market 2025-2033: 17.6% CAGR to $14.6B

The Gene Panel Market Report shows a base year 2025 valuation of $4.01 billion, expanding to $14.64 billion by 2033 at 17.6% CAGR. Growth is concentrated in oncology, rare disease diagnostics, and pharmacogenetics. North America holds 38% revenue share due to high NGS adoption, favorable reimbursement, and dense hospital diagnostic infrastructure. Asia-Pacific is the fastest-growing region at 19.8% CAGR, driven by expanding cancer screening and pharma research.

• Test kits dominate product revenue at 58% share, while testing services grow at 18.9% CAGR.
• The Hospital & Diagnostic Laboratories Market accounts for 46% of end-use demand.
• The Cancer Risk Assessment Gene Panel Market represents 31% of application revenue.
• The Customized Gene Panel Market grows at 20.1% CAGR as precision medicine expands.
• The Next-Generation Sequencing Market enables panel scalability and reduces cost per sample.
• The Molecular Diagnostics Market parent valuation supports double-digit expansion through 2033.

Macro drivers include aging populations, declining sequencing costs, and companion diagnostic approvals. Restraints include reimbursement variability across geographies, variant interpretation complexity, and shortages of certified molecular pathologists. The Gene Panel Test Kits Market benefits from workflow bundling and reagent consistency, while the Amplicon Based Gene Panel Market serves cost-sensitive screening programs. The Pharmaceutical & Biotechnology Companies Market increasingly adopts custom panels for clinical trial enrichment.

Segment Analysis Matrix

The Gene Panel Test Kits Market is the largest revenue-generating segment, reaching an estimated $2.33 billion in 2025. Test kits include predesigned and customized reagents, with predesigned kits accounting for 62% of kit revenue. The Amplicon Based Gene Panel Market is favored for targeted hotspot testing because of lower input DNA requirements and faster turnaround. Hybridization-based panels capture larger genomic regions and dominate oncology comprehensive profiling.

• Amplicon-based panels grow at 17.4% CAGR, limited by lower multiplexing capacity.
• Hybridization-based panels grow at 18.8% CAGR, supported by broad cancer panels.
• Customized Gene Panel Market expands at 20.1% CAGR, driven by pharma trial demand.

• Reagent price competition compresses test kit gross margins to 58-62% from 65% in 2022.
• Testing services face pricing pressure from hospital lab insourcing, with margins near 35-40%.
• Custom panels command premium pricing but require costly bioinformatics and validation.

The Hospital & Diagnostic Laboratories Market remains the anchor end-use segment, but the Pharmaceutical & Biotechnology Companies Market is the fastest-growing buyer group as drug developers require pharmacogenomic and biomarker panels for trial enrollment.

Market Dynamics Impact Analysis

Driver impact is quantified by a 1.8x increase in companion diagnostic approvals from 2020 to 2024, directly lifting oncology panel volumes. Cost declines in the Next-Generation Sequencing Market have reduced panel sequencing expense by 40% over five years, widening clinical access. The Cancer Risk Assessment Gene Panel Market expands as hereditary cancer testing guidelines broaden to include more genes.

Restraints are concentrated in reimbursement and workforce capacity. Only 54% of broad panels receive full coverage in major markets, creating a $0.6 billion annual revenue gap. Molecular pathologist shortages add 2-4 weeks to turnaround times in some hospital systems, slowing adoption. Data localization rules in the European Union and China increase compliance costs by 8-12% for cross-border testing services.

Vendor Benchmarking Matrix

• Illumina Inc.: Holds the largest installed base of sequencers and a 62% share of NGS panel content revenue; its panel menu spans oncology, inherited disease, and pharmacogenomics.
• Thermo Fisher Scientific: Uses Ion Torrent and Oncomine assets to serve oncology diagnostics with comprehensive genomic profiling and companion diagnostic partnerships.
• Agilent Technologies: Supplies SureSelect hybridization capture reagents and licenses content to pharma and academic labs, supporting customized panel growth.
• Qiagen Inc.: Combines sample preparation and QIAseq panel kits, targeting hospital labs that require automated workflows and low input DNA protocols.
• Guardant Health, Inc.: Focuses on liquid biopsy panels for therapy selection and recurrence monitoring, with growing adoption in oncology clinics.
• Foundation Medicine Inc.: Provides broad genomic profiling for pharma and oncology; its panels are used in over 500 clinical trials worldwide.
• Myriad Genetic Laboratories: Maintains a niche in hereditary cancer panels, especially BRCA and multi-gene risk assessment for diagnostic labs.
• Bio-Rad Laboratories: Offers droplet digital PCR panels for low-plex applications, competing with NGS in cost-sensitive research settings.
• Personalis: Differentiates with immunogenomics and minimal residual disease panels for pharmaceutical trials and translational research.
• Cepheid: Delivers point-of-care molecular panels, expanding gene panel access in hospital labs with rapid turnaround needs.
• Eurofins Genomics: Competing in testing services with global sequencing capacity and bioinformatics support for research institutes.

Latest Strategic Moves

• Q1 2024: Illumina launched a 500-gene cancer panel, increasing content breadth for comprehensive genomic profiling and pressuring competitors to expand panel sizes.
• Q2 2024: Thermo Fisher Scientific formed a companion diagnostic partnership with a pharmaceutical firm, tying panel revenue to drug approval pathways and improving reimbursement predictability.
• Q3 2024: Guardant Health acquired a liquid biopsy software company, adding variant interpretation and workflow tools to its panel services and strengthening its oncology clinic presence.
• Q1 2025: Qiagen released an automated NGS panel workflow, reducing hands-on time by 30% and targeting hospital labs with limited molecular pathology staff.
• Q2 2025: Agilent Technologies licensed hybridization capture intellectual property, expanding its customized panel supply to pharma and research customers.

Regional Growth Comparison

• North America remains the most mature market, with $1.52 billion in 2025 revenue and 16.8% CAGR. The United States accounts for 89% of regional value, supported by Medicare coverage for hereditary cancer panels and high NGS lab density.
• Europe grows at 17.2% CAGR, driven by national genomic medicine programs in the United Kingdom, France, and Germany. Strict EU data privacy rules increase compliance costs but also build clinical trust in gene panel diagnostics.
• Asia-Pacific is the fastest-growing region at 19.8% CAGR, with China and India expanding hospital laboratory networks. The Hospital & Diagnostic Laboratories Market in this region benefits from rising cancer incidence and lower-cost NGS platforms.
• LAMEA grows at 18.5% CAGR, led by Brazil and GCC countries investing in oncology infrastructure and clinical trial capacity. South Africa and Israel serve as regional hubs for customized gene panel services.

Upstream dependencies shape cost and lead times across panel production. The DNA Oligonucleotide Synthesis Market supplies short single-stranded sequences that are critical for amplicon and hybridization capture panels. High-purity oligonucleotides account for 18-22% of test kit material costs, with prices rising 6% in 2024 due to shipping and raw chemical shortages.

• Oligonucleotide synthesis capacity is concentrated in Asia, creating 4-8 week lead-time risks during demand surges.
• dNTP price volatility reached 12% in 2024, driven by raw chemical shortages and freight disruptions.
• Enzyme suppliers have improved capacity, but cold-chain logistics still add 3-5% to landed material costs.
• The Next-Generation Sequencing Market depends on these inputs, so panel manufacturers use dual sourcing to reduce single-vendor exposure.

Average selling prices vary by panel type and service model. Predesigned test kits sell for $200-$800 per sample, while customized panels command $1,500-$5,000 per sample. Testing services are priced at $400-$2,500 per sample, with liquid biopsy panels at the higher end due to specialized workflows.

• Gross margins for test kits declined to 58-62% in 2025 from 65% in 2022 as reagent competition intensified.
• Testing services face 35-40% operating margins, pressured by hospital lab insourcing and price transparency.
• Customized Gene Panel Market participants retain stronger pricing power, with margins near 55-60% when tied to pharma trials.
• Falling sequencing costs reduce consumable expenses but do not offset rising reagent and labor costs.
• The Molecular Diagnostics Market remains sensitive to reimbursement cuts, which can lower ASPs for standard oncology panels by 3-5% annually.

• 1. Product & Services
  • 1.1. Test Kits
  • 1.2. Testing Services
• 2. Techniques
  • 2.1. Amplicon Based Approach
  • 2.2. Hybridization Based Approach
• 3. Design
  • 3.1. Predesigned Gene Panel
  • 3.2. Customized Gene Panel
• 4. End-use
  • 4.1. Academic & Research Institutes
  • 4.2. Hospital & Diagnostic Laboratories
  • 4.3. Pharmaceutical & Biotechnology Companies
• 5. Application
  • 5.1. Cancer Risk Assessment
  • 5.2. Diagnosis of Congenital Diseases
  • 5.3. Pharmacogenetics
  • 5.4. Other Applications

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific